HJLI
Income statement / Annual
Last year (2023), enVVeno Medical Corporation's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, enVVeno Medical Corporation's net income was -$23.52 M.
See enVVeno Medical Corporation,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$31,243.00 |
$186,552.00 |
$422,111.00 |
$785,912.00 |
$0.00 |
$236,500.00 |
Cost of Revenue |
$546,000.00
|
$525,000.00
|
$452,909.00
|
$383,972.00
|
$0.00
|
$0.00
|
$419,659.00
|
$810,294.00
|
$125,423.00
|
$132,315.00
|
Gross Profit |
-$546,000.00
|
-$525,000.00
|
-$452,909.00
|
-$383,972.00
|
$31,243.00
|
$186,552.00
|
$2,452.00
|
-$24,382.00
|
-$125,423.00
|
$104,185.00
|
Gross Profit Ratio |
0
|
0
|
0
|
0
|
1
|
1
|
0.01
|
-0.03
|
0
|
0.44
|
Research and Development Expenses |
$13.58 M
|
$9.91 M
|
$5.73 M
|
$4.25 M
|
$2.21 M
|
$1.24 M
|
$649,736.00
|
$0.00
|
$0.00
|
$0.00
|
General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$11.66 M
|
$15.02 M
|
$11.16 M
|
$4.88 M
|
$4.91 M
|
$6.48 M
|
$5.46 M
|
$4.63 M
|
$1.29 M
|
$1.06 M
|
Other Expenses |
$0.00
|
$0.00
|
$33,272.00
|
-$215,906.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Operating Expenses |
$25.24 M
|
$24.93 M
|
$16.89 M
|
$9.14 M
|
$7.12 M
|
$7.72 M
|
$6.11 M
|
$4.63 M
|
$1.29 M
|
$1.06 M
|
Cost And Expenses |
$25.24 M
|
$24.93 M
|
$16.89 M
|
$9.14 M
|
$7.12 M
|
$7.72 M
|
$6.53 M
|
$5.45 M
|
$1.29 M
|
$1.19 M
|
Interest Income |
$180,000.00
|
$161,000.00
|
$19,000.00
|
$3,739.00
|
$49,915.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$65,493.00
|
Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$6.86 M
|
$209,506.00
|
$57,890.00
|
$88,524.00
|
$0.00
|
Depreciation & Amortization |
$220,000.00
|
$525,000.00
|
$452,909.00
|
$383,972.00
|
$396,665.00
|
$133,420.00
|
$139,213.00
|
$151,174.00
|
$125,423.00
|
$134,127.00
|
EBITDA |
-$25.02 M |
-$24.51 M |
-$16.75 M |
-$8.75 M |
-$6.96 M |
-$6.05 M |
-$5.73 M |
-$5.38 M |
-$1.16 M |
-$818,532.00 |
EBITDA Ratio |
0
|
0
|
0
|
0
|
-212.52
|
-39.68
|
-18.18
|
-5.74
|
0
|
-3.46
|
Operating Income Ratio |
0
|
0
|
0
|
0
|
-245.67
|
-42.11
|
-14.46
|
-5.93
|
0
|
-4.03
|
Total Other Income/Expenses Net |
$1.72 M
|
$263,000.00
|
$364,681.00
|
-$360.00
|
$49,915.00
|
-$5.19 M
|
-$1.69 M
|
-$929,075.00
|
-$88,347.00
|
-$65,493.00
|
Income Before Tax |
-$23.52 M
|
-$24.67 M
|
-$16.53 M
|
-$9.14 M
|
-$7.63 M
|
-$13.04 M
|
-$7.79 M
|
-$5.59 M
|
-$1.38 M
|
-$1.02 M
|
Income Before Tax Ratio |
0
|
0
|
0
|
0
|
-244.07
|
-69.91
|
-18.46
|
-7.11
|
0
|
-4.31
|
Income Tax Expense |
$0.00
|
-$365,000.00
|
-$331,409.00
|
-$215,546.00
|
$863,542.00
|
$1.67 M
|
$209,506.00
|
-$2.14 M
|
$314,339.00
|
$0.00
|
Net Income |
-$23.52 M
|
-$24.30 M
|
-$16.20 M
|
-$8.92 M
|
-$7.63 M
|
-$13.04 M
|
-$7.79 M
|
-$3.39 M
|
-$1.60 M
|
-$1.02 M
|
Net Income Ratio |
0
|
0
|
0
|
0
|
-244.07
|
-69.91
|
-18.46
|
-4.31
|
0
|
-4.31
|
EPS |
-1.91 |
-2.16 |
-1.87 |
-6.91 |
-12.1 |
-34.83 |
-20.1 |
-7.72 |
-3.66 |
-4.26 |
EPS Diluted |
-1.91 |
-2.16 |
-1.87 |
-6.91 |
-12.1 |
-34.83 |
-20.1 |
-7.72 |
-3.66 |
-4.24 |
Weighted Average Shares Out |
$12.30 M
|
$11.23 M
|
$8.68 M
|
$1.29 M
|
$630,417.00
|
$374,498.00
|
$387,691.00
|
$438,718.00
|
$438,718.00
|
$239,000.00
|
Weighted Average Shares Out Diluted |
$12.30 M
|
$11.23 M
|
$8.68 M
|
$1.29 M
|
$630,417.00
|
$374,498.00
|
$387,691.00
|
$438,718.00
|
$438,718.00
|
$240,000.00
|
Link |
|
|
|
|
|
|
|
|
|
|